Jiangsu Hengrui Pharmaceuticals Co.,Ltd

¥50.43As of Sun 8 Nov 2026, 12:00 UTC
SSE:600276Healthcare
Country China
PE (Fwd) •••
TSR 10Y CAGR 11.74%
Div yield 0.40%
ROE 13.94%
Drug Manufacturers (Specialty & Generic)
Beta (5Y) 0.04
PE TTM 37.66
TSR TTM (21.07%)
Mkt cap ¥332.2B
ROIC 31.67%
SE Grade™
Value
Quality
Moat
Consensus
Reference
¥63
24.40%
(83.10%)
Hold 7|6|3|7|7
4Q25
1Q26
2Q26
3Q26
Earnings per share¥
0.51
0.50
0.56
0.54
9.64%
(1.51%)
14.00%
1.86%
Revenue¥B
16.63
17.26
17.60
17.59
6.89%
12.44%
11.56%
7.86%
Peers (US$49.80B)
Cap (US$)
PE
16.31B
—
14.75B
18.94x
49.72B
99.82x
Capital
TTM
5Y
10Y
Leveragex
4.541
0.380
0.279
EBIT/Intx
7.457
0.090
0.100
Own earn%
(280.45)
292.81
260.23
Sh yield%
27.36
6.60
6.71
Owners
Insiders/Inst%
1.46
32.45
Short interest%
4.06
SBC / revenue%
5.86
Record
10Y
Profitable years
10/10
Revenue growth years
10/10
EPS growth years
10/10
Dividend streakyrs
19
Op margin range%
12–17
$1 testx
−0.1
Incr. ROIC%
7

Jiangsu Hengrui Pharmaceuticals Co.,Ltd is a pharmaceutical company that researches, develops, manufactures, and commercializes medicines addressing unmet clinical needs in China and internationally. Its medicines cover oncology, metabolic and cardiovascular, immunological and respiratory, neuroscience, pain management, infectious, respiratory system, hematological, ophthalmology, and autoimmune and other diseases.